{"filings":[{"id":2834399,"accession_number":"0001213900-26-099416","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-09-11T23:59:23+00:00","items":["5.07"],"status":"ready","headline":"Polaryx shareholders re-elect Alex Yang, Mitchel Berger as Class I directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alex Yang and Mitchel Berger re-elected as Class I directors at Sept 10, 2026 annual meeting.","Each director received 30,072,137 votes for, 332 withheld, with 472,610 broker non-votes.","Ratification of Grant Thorton LLP as auditor for FY2026 approved: 30,510,106 for, 34,973 against.","Directors will serve until the 2029 annual meeting of stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2604963,"accession_number":"0001213900-26-096235","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-09-01T20:30:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.","Previously SVP Clinical Development at Tyra Biosciences; led Phase 2 rare disease trial; also CMO at Spruce Biosciences.","SOTERIA Phase 2 trial of PLX-200 in CLN2, CLN3, Krabbe, Sandhoff diseases; FDA safe-to-proceed Oct 2025; initiation planned Q4 2026.","Dr. Charlton's background includes roles at 89bio, Ascendis Pharma, Allergan; board-certified pediatric endocrinologist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1776196,"accession_number":"0001213900-26-080041","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-07-21T20:30:46+00:00","items":["5.02"],"status":"ready","headline":"Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately.","Company states resignation will not affect clinical timelines, regulatory plans, or development strategy.","Search for successor commenced; existing leadership team will assume CMO responsibilities in interim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1701356,"accession_number":"0001213900-26-078912","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-07-17T12:00:26+00:00","items":["5.08","8.01"],"status":"ready","headline":"Polaryx sets 2026 annual meeting for Sept 10; record date July 27","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting will be held virtually on September 10, 2026.","Record date for voting is July 27, 2026; no annual meeting was held in 2025.","Stockholder proposals under Rule 14a-8 must be received by July 27, 2026.","Director nominations and other proposals after July 27 will be deemed untimely.","Proposals must comply with SEC rules, Nevada law, and company bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":722836,"accession_number":"0001213900-26-062155","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-05-28T20:31:45+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.","Largest stockholder MStone Partners Healthcare purchased 88,453 shares ($360k) in the offering.","Net proceeds will fund initiation of Phase 2 SOTERIA trial (CLN2, CLN3, Krabbe, Sandhoff) and extend cash runway through Q2 2027.","No resale registration statement will be filed; shares issued under Section 4(a)(2) and Regulation S exemption.","FDA Fast Track Designation already in place for all four planned LSD indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}